4D Molecular Therapeutics (FDMT) Cash from Financing Activities (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Cash from Financing Activities for 7 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $124.4 million (up 575.67% YoY), while the FY2025 annual figure was $113.0 million, down 66.51% from the prior year.
• Cash from Financing Activities slipped to $11.5 million in Q1 2026 per FDMT's latest filing, from $112.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $318.8 million in Q1 2024 and bottomed at -$50000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $38.9 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 106.1% — and 2023, when it surged 261138.0%.
• 4D Molecular Therapeutics' Cash from Financing Activities stood at $2.0 million in 2022, then jumped by 132.75% to $4.8 million in 2023, then plunged by 87.38% to $601000.0 in 2024, then jumped by 18532.61% to $112.0 million in 2025, then plunged by 89.74% to $11.5 million in 2026.
• Business Quant data shows FDMT's Cash from Financing Activities at $11.5 million in Q1 2026, $112.0 million in Q4 2025, and $116000.0 in Q3 2025.